Clinical trials: Multiple Sclerosis, Relapsing-remitting
Multiple Sclerosis, Relapsing-Remitting
Phase I BP Interferon (IFN) Beta-004
Phase I study aiming at: establishing the pharmacokinetic profile of interferon beta-1a after i.v. administration of the formulation BioPartners IFN beta-1a without albumin (HSA-free solution in pre-filled syringes) at 18 MIU…
- Trial name
- NCT02517788
- Testing
- Interferon beta-1a HSA-free biosimilar, Interferon beta-1a HSA+ biosimilar, Interferon beta-1a original
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Multiple Sclerosis, Relapsing-Remitting
Cognition and MRI Markers in MS Patients With Aubagio® Treatment
Cognitive impairment is nowadays more and more recognized as an important feature of the multiple sclerosis (MS) disease which contributes largely to disability.
- Trial name
- AUBACOG (NCT03768648)
- Testing
- Clinical assessment, Ecological evaluation, Neuropsychological evaluation
- Where
- France
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Multiple Sclerosis, Relapsing-Remitting, Neuromyelitis Optica
PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.
Central Nervous System (CNS) demyelinating conditions include multiple sclerosis (MS), Acute Disseminated Encephalomyelitis (ADEM), Neuromyelitis Optica Spectrum Disorder (NMOSD), Optic Neuritis (ON) and Transverse Myelitis (TM).
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, Transverse Myelitis
- Trial name
- SONICS (NCT03942952)
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Multiple Sclerosis
Multiple Sclerosis and Respiratory and Functional Capacity
It is known that respiratory functions, physical activities and functional capacities of Multiple Sclerosis (MS) patients decrease with the progression of the disease.
- Trial name
- NCT05697523
- Testing
- Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Nigde Omer Halisdemir University
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Cortical Lesions in Patients With Multiple Sclerosis
Multiple sclerosis (MS) is an autoimmune disease, leading to inflammation and degeneration of neurons in the entire central nervous system (CNS).
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
- Trial name
- CLiMS (NCT03653585)
- Where
- Denmark
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Danish Research Centre for Magnetic Resonance
Multiple Sclerosis (MS) - Relapsing-remitting
Educational Programs Based on Healthy Habits to Improve Quality of Life and Psychosocial Profile in Women With Neurodegenerative Diseases: The ADVICE Protocol Study (Phase 1)
This phase of the project aims to analyze the interaction between physical exercise and the phases of the menstrual cycle, evaluating its impact on fatigue, functional capacity, and exercise perception in women with and without…
- Trial name
- ADVICE Phase 1 (NCT06925022)
- Testing
- Strength training session during Early Follicular Phase, Strength Training Protocol during Late Follicular Phase, Strength Training during Mid-Luteal Phase
- Where
- Spain
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Universidad de Almeria
Multiple Sclerosis, Relapsing-Remitting, Optic Neuritis
Light Stimulation to Improve Visual Function After Optic Neuritis in Persons with Multiple Sclerosis
The aim of this monocentric randomized controlled intervention study is to improve visual function in persons with multiple sclerosis following optic neuritis (neuritis nervi optici) by means of a light stimulation.
- Trial name
- ONSTIM (NCT06389968)
- Testing
- Light stimulation
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Technical University of Munich
Relapsing Remitting Multiple Sclerosis
Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects
A single-dose, randomized, open-label, two-way crossover, two-period, two-sequence, two-treatment, single-center, bioequivalence study of Bafiertam and Vumerity.
- Trial name
- NCT05181215
- Testing
- Monomethyl Fumarate 190 Mg, Diroximel Fumarate 462 mg
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Banner Life Sciences LLC
Multiple Sclerosis, Remitting-Relapsing Multiple Sclerosis
Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis
Fatigue is a prevalent symptom in patients with multiple sclerosis (MS) and is associated with considerable impairment in quality of life as well as loss of occupational capacity.
- Conditions
- Multiple Sclerosis, Remitting-Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progress Multiple Sclerosis
- Trial name
- NCT07426991
- Testing
- No Intervention: Observational Cohort
- Where
- 2 sites in Germany
- Volunteers
- 837 people, healthy volunteers welcome
- Sponsor
- Heinrich-Heine University, Duesseldorf
Multiple Sclerosis
Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?
Primary Aims: To determine how effective long term Natalizumab (NTZ) therapy is in slowing the progression of whole brain atrophy.
- Trial name
- NCT02588053
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Multiple Sclerosis, Relapsing-Remitting
Polymorphisms of Interleukins, Glypican, and Human Leukocyte Antigen Genes and Treatment Response in Multiple Sclerosis.
HLA-DRB1 * Gene and some genes involved in inflammation and immunity (IL-7R, GPC5, CTSS) have been linked to risk of MS and the response to treatment with immunomodulators.
- Trial name
- WESTEMDRB1 (NCT02769767)
- Testing
- Polymorphism of Interleukins, Glypican, and Human Leukocyte Antigen Genes.
- Where
- Mexico
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Instituto Jalisciense de Cancerologia
Multiple Sclerosis, Relapsing-Remitting
A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.
GSK2018682 is a potent and selective agonist for the sphingosine-1- phosphate receptor subtype 1 (S1P1) with the potential to be an effective treatment for multiple sclerosis (MS).
- Trial name
- P1A114919 (NCT01466322)
- Testing
- GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Relapsing Remitting Multiple Sclerosis
Comparative Study of High-Efficacy Disease Modifying Treatment of Relapsing Multiple Sclerosis
The goal of this prospective, multi-center, non-blinded, non-randomized, non-intervention clinical trial is to compare immunologic, virologic and epigenetic factors in patients with active multiple sclerosis in standard 2.line…
- Trial name
- CoSHEDRMS (NCT06159712)
- Testing
- Blood samples
- Where
- Denmark
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Relapsing Remitting Multiple Sclerosis
Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment
In this study the investigators wish to test the hypothesis that the repertoire of solutes secreted by leukocytes isolated from patients with relapsing-remitting forms of Multiple Sclerosis (MS) following 6 months of treatment…
- Trial name
- NCT05171972
- Testing
- Ofatumumab
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Multiple Sclerosis, Relapsing-Remitting
Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio)
The study is a two-year prospective observational study of patients treated with teriflunomide. The investigators will recruit up to 75 patients at baseline, based on the estimate that approximately 20% of these patients (~ 15…
- Trial name
- NCT03561402
- Testing
- Teriflunomide
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- McGill University
Multiple Sclerosis, Relapsing-Remitting
Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of Firategrast to Investigate How Quickly Absorption From the Digestive System Takes Place.
This study will investigate how 3 new types of drug formulations are absorbed by the body. This study is termed 'open-label', which means volunteers will be aware of which treatment they are receiving.
- Trial name
- NCT01424462
- Testing
- A, B, C
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis (MS), Relapsing-remitting Multiple Sclerosis (RRMS)
Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis
This project is to: 1. Quantify differences in axonal integrity and organization in aMS versus naPMS patients. 2. Quantify changes in axonal integrity and organization in aMS versus naPMS patients over a two-year period. 3.
- Conditions
- Multiple Sclerosis (MS), Relapsing-remitting Multiple Sclerosis (RRMS), Secondary-progressive Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS)
- Trial name
- INsIDER (NCT05177523)
- Testing
- MRI, Neurocognitive examination for healthy subjects, blood sampling
- Where
- Switzerland
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Multiple Sclerosis
Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis
The purpose of this study is to determine whether glatiramer acetate (Copaxone) will induce anti-inflammatory type II monocyte development during treatment of MS, and if these antigen presenting cells (APC) will promote Th2 and…
- Trial name
- NCT00819195
- Testing
- Glatiramer acetate
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Multiple Sclerosis
Th Effects of Aubagio on Brain Pathology in Multiple Sclerosis Studied Over 12 Months
This study will evaluate the effects of Aubagio on changes in the brain using MRI.
- Trial name
- GZA (NCT01881191)
- Testing
- MRI
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University at Buffalo
Multiple Sclerosis, Clinically Isolated Syndrome
Visual Processing Speed and Objective Analysis of Ocular Movements in Multiple Sclerosis
This project aims to analyze ocular motility problems, visual processing speed and microperimetry, and their relationship with consolidated retinal structural biomarkers (optical coherence tomography, OCT) in patients with…
- Conditions
- Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis
- Trial name
- NCT05706220
- Testing
- Eye tracking, Microperimetry, Optical coherence tomography (OCT)
- Where
- Spain
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA